Evidence mapPaperPMID 40838211Full record

ArticleMaterials today. Bio2025

Hybrid biomaterials-based radiosensitizers: Preparations and their applications in enhancing tumor radiotherapy.

Jia Liu, Lin Zhao, Yang Sun, Qinrui Fu, Wenjing Xiao

Abstract read
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Current Perspectives on Radiosensitizers in Cancer Radiotherapy.International journal of nanomedicine · 2026
    Review
  5. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jia LiuDepartment of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Lin ZhaoDepartment of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Yang SunDepartment of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.
Qinrui FuInstitute of Chronic Disease, College of Medicine, Qingdao University, Qingdao, 266071, China.
Wenjing XiaoDepartment of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, 266003, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiotherapy is a critical modality in cancer treatment, yet its efficacy can be substantially hindered by the tumor microenvironment. Nanotechnology has empowered nanomaterials to assume multifunctional roles. These roles encompass drug delivery, radiosensitization, imaging, inducing DNA damage, and decreasing glutathione (GSH) levels to impede the neutralization of reactive oxygen species (ROS), thus enhancing therapeutic efficacy. Consequently, hybrid materials integrating multiple functional components have garnered significant attention. In recent years, the development of hybrid biomaterials-based radiosensitizers has successfully addressed these challenges and attracted considerable interest. This review systematically summarizes the synthesis methods, composition, and potential applications of hybrid biomaterials-based radiosensitizers in radiotherapy. The synthesis techniques are classified into self-assembly, chemical synthesis, and biomimetic synthesis. Furthermore, we examine various types of inorganic, inorganic-organic, and organic hybrid biomaterials-based radiosensitizers, with an emphasis on their mechanisms of action, including enhancing ionizing radiation effects, alleviating tumor hypoxia, and depleting GSH. Finally, we discuss the future prospects and existing challenges of hybrid biomaterials-based radiosensitizers in cancer therapy, highlighting their potential to markedly improve therapeutic efficacy.

Indexed as

Hybrid biomaterials-based radiosensitizersNanomedicineRadiotherapyReactive oxygen speciesSynergistic therapy

Identifiers

PMID40838211
PMCPMC12363587

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.